These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 16732002

  • 1. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes.
    Ackermann RT, Marrero DG, Hicks KA, Hoerger TJ, Sorensen S, Zhang P, Engelgau MM, Ratner RE, Herman WH.
    Diabetes Care; 2006 Jun; 29(6):1237-41. PubMed ID: 16732002
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
    Caro JJ, Getsios D, Caro I, Klittich WS, O'Brien JA.
    Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
    Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE, Diabetes Prevention Program Research Group.
    Ann Intern Med; 2005 Mar 01; 142(5):323-32. PubMed ID: 15738451
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV, Frick KD, Wade A, Simko R, Burge R.
    Clin Ther; 2009 Apr 01; 31(4):862-79. PubMed ID: 19446159
    [Abstract] [Full Text] [Related]

  • 10. Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases.
    Annemans L, Lamotte M, Clarys P, Van den Abeele E.
    Eur J Cardiovasc Prev Rehabil; 2007 Dec 01; 14(6):815-24. PubMed ID: 18043305
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN).
    Wolf AM, Siadaty M, Yaeger B, Conaway MR, Crowther JQ, Nadler JL, Bovbjerg VE.
    J Am Diet Assoc; 2007 Aug 01; 107(8):1365-73. PubMed ID: 17659904
    [Abstract] [Full Text] [Related]

  • 14. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study.
    Lindström J, Peltonen M, Eriksson JG, Aunola S, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Uusitupa M, Tuomilehto J, Finnish Diabetes Prevention Study (DPS) Group.
    Diabetes Care; 2008 May 01; 31(5):857-62. PubMed ID: 18252900
    [Abstract] [Full Text] [Related]

  • 15. Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations?
    Honkanen LA, Mushlin AI, Lachs M, Schackman BR.
    J Am Geriatr Soc; 2006 Nov 01; 54(11):1658-65. PubMed ID: 17087691
    [Abstract] [Full Text] [Related]

  • 16. Impact of a managed-Medicare physical activity benefit on health care utilization and costs in older adults with diabetes.
    Nguyen HQ, Ackermann RT, Berke EM, Cheadle A, Williams B, Lin E, Maciejewski ML, LoGerfo JP.
    Diabetes Care; 2007 Jan 01; 30(1):43-8. PubMed ID: 17192331
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM, Brisson M, Levin MJ.
    Vaccine; 2007 Nov 28; 25(49):8326-37. PubMed ID: 17980938
    [Abstract] [Full Text] [Related]

  • 18. The impact of prevention on reducing the burden of cardiovascular disease.
    Kahn R, Robertson RM, Smith R, Eddy D.
    Circulation; 2008 Jul 29; 118(5):576-85. PubMed ID: 18606915
    [Abstract] [Full Text] [Related]

  • 19. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.
    Icks A, Rathmann W, Haastert B, Gandjour A, Holle R, John J, Giani G, KORA Study Group.
    Diabet Med; 2007 May 29; 24(5):473-80. PubMed ID: 17381502
    [Abstract] [Full Text] [Related]

  • 20. The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action.
    Bemelmans W, van Baal P, Wendel-Vos W, Schuit J, Feskens E, Ament A, Hoogenveen R.
    Prev Med; 2008 Feb 29; 46(2):127-32. PubMed ID: 17822752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.